The one-year clinical fellowship features a six-month training in the Addiction Medicine Services at the UPMC Western Psychiatric Hospital and a six-month training at the Veteran’s Administration Pittsburgh Health System (VAPHS). Fellows are members of fully-integrated teams at both the UPMC Western Psychiatric Hospital and the VAPHS.
Rotations through UPMC Western Psychiatric Hospital:
The 28-bed dual diagnosis unit at the UPMC Western Psychiatric Hospital provides the full range of assessment and treatment of patients with substance use and co-occurring disorders. It provides individual, group, and family therapies in addition to pharmacotherapy. Motivational Interviewing and integrating pharmacological approaches with psychosocial treatments are the focus of the rotation. The fellows are an integral part of the treatment team and provide supervision to psychiatry residents, medical students, and clinical psychology interns.
Fellows learn how to utilize the various detoxification protocols and the overall management of patients in the 18-bed acute medically-managed inpatient detoxification unit at UPMC Mercy. This unit serves patients with substance use disorders at risk for complicated withdrawal from opioids, alcohol, and sedative hypnotics.
The ambulatory detoxification program is offered at the Center for Psychiatric and Chemical Dependency Services in collaboration with the UPMC Western Psychiatric Hospital Diagnostic Evaluation Center. Patients who do not meet the criteria for inpatient detoxification are treated for withdrawal from opioids, alcohol and sedative hypnotics and linked to outpatient care.
The services provided at CPCDS include outpatient detoxification for alcohol, sedative hypnotics and opioids, individual outpatient addiction treatment for all major drugs of abuse, and intensive outpatient program services for adults, young adults, and adolescents. Addictions commonly treated at CPCDS include alcohol, cocaine and amphetamines, benzodiazepines, opioid, marijuana, tobacco, and behavioral addictions. CPCDS also provides treatment for patients with co-occurring disorders, and medication-assisted treatments such as buprenorphine for opioid use disorders and naltrexone extended release (VIVITROL). Fellows will maintain a caseload of adults, young adults, and adolescents throughout the rotation.
This specialized women’s program offers coordinated medical, obstetrical, pediatric, and psychosocial care and individualized outpatient treatment for pregnant women and mothers with substance use disorders. Many of the women in PAC also receive methadone treatment at the Narcotic Addiction Treatment Program (NATP) - a licensed methadone clinic that provides opioid agonist treatment to patients, including pregnant women. PAC collaborates with Magee Women’s Hospital’s Pregnancy Recovery Center (PRC) and provides the counseling component of the management of pregnant women receiving buprenorphine treatment for opioid use disorder. Fellows are assigned a caseload of pregnant patients to manage and work very closely with the treatment team and obstetrical team at Magee Women’s Hospital.
The Narcotic Addiction Treatment Program is a comprehensive outpatient treatment program that provides integrated care and medication-assisted treatment (i.e. methadone and buprenorphine) for patients with opioid use disorders and co-occurring psychiatric disorders. Fellows are assigned a caseload of patients to manage and work closely with the treatment team.
Rotations through VAPHS:
The Center for Treatment of Addictive Disorders Outpatient Rehabilitation and Education (CORE) Program is a 20 patient capacity 14- to 21-day intensive intervention that is held in both residential and non-residential settings. The majority of the patients involved in the program have substance use and co-occurring psychiatric disorders. Fellows are assigned a caseload of patients to manage as part of their treatment team.
This is a medication-assisted clinic for patients with opioid use disorders that utilizes methadone and buprenorphine and has the capacity to serve up to 120 patients. A significant proportion of patients participating in this program are dually-diagnosed. Fellows are assigned a caseload of patients to manage as part of their treatment team.
The program utilizes buprenorphine for the treatment of opioid dependence in various clinical locations including the Center for the Treatment of Addictive Disorders, Rapid Access Clinics, and the Substance Abuse Day Program. Fellows are assigned a caseload of patients to manage as part of their treatment team.